EyePoint stock: buy or sell?
February 25th, 2020
Should I buy EyePoint stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Trading strategies are meant for helping you in the decision process of what stocks to choose and when is the best time to buy them. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with EyePoint Pharmaceuticals stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is EyePoint stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for EYPT stock for the last month.
EyePoint stock analysis
EyePoint collapsed a bloodcurdling -4.23% and closed at $1.36.
EyePoint collapsed a bloodcurdling -4.23% and closed at $1.36. Since December when SMA100d and SMA200d crossed up, EYPT price slipped $-0.16 per share (-10.53%).
EyePoint plunged a bloodcurdling -6.21% this week. Late January EYPT boosted an amazing 11.92% in just one week. This was the 5th red week in a row, sliding in full a -33.53%.
EyePoint Pharmaceuticals stock just marked a top under its last top. Athought it's not a big concern right now, investors in EYPT should be alerted as this could be a warning for future complications. It's important EYPT stock price keeps the level, and maybe bounce up from there forming a double bottom configuration. Since last week, when EYPT stock price broke down the 40-weeks moving avarage line, it slid $-0.42 per share (-23.60%). Stocks below the 200d moving average line are usually not recommended for average traders. Since early December 2019 when SMA20w and SMA40w crossed up, EYPT price slipped $-0.14 per share (-9.33%).
EyePoint stock price history
EyePoint IPO was on January 27th, 2005 at $42.00 per share1. Since then, EYPT stock lost a -96.80%, with a yearly average of -6.50%.
1: Adjusted price after possible price splits or reverse-splits.
EyePoint stock historical price chart
EYPT stock reached 52-week highs at $2.79, and all-time highs 2005-01-27 with a price of 48.56.
EyePoint stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' EYPT stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price target for EyePoint stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, EyePoint Pharmaceuticals failed to meet the expectations of the analysts and reported an awful EPS of $-0.12 per share when experts were expecting $-0.14.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a frightening correction of -60.72% to $2.96 M dollars. When comparing 2018 vs 2017, likewise, profit margin (that is, the net income divided by revenues) plummed a -1,550.52% to -1,795.71%. EyePoint fiscal year ends in June, and to evaluate its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, EyePoint TTM sales up to December 2018 were $4.57 and earnings $-86.13 million dollars. When comparing this TTM figures with the last reported annuality, we can review EyePoint Pharmaceuticals business evolution since June 2018: Annual revenues up to December, compared to lastest yearly report, climbed an outstanding 54.37%. In contrast, profit margin (net income/sales) collapsed at -1,795.71%.
|2013||$2.14 M||-||$-11.90 M-556.1%||-|
|2014||$3.47 M||62.15%||$-13.36 M-385.0%||12.27%|
|2015||$27 M||665.56%||$6.35 M23.9%||-147.51%|
|2016||$1.62 M||-93.90%||$-21.55 M-1330.1%||-439.48%|
|2017||$7.54 M||365.37%||$-18.49 M-245.2%||-14.21%|
|2018||$2.96 M||-60.72%||$-53.17 M-1795.7%||187.64%|
|TTM||$4.57 M||54.37%||$-86.13 M-1884.2%||61.98%|
Quarterly financial resultsEyePoint reported $2.44 M in revenues for 2018-Q4, a 402.47% up compared to previous quarter. Reported quarter income marked $-11.59 million with a profit margin of -474.77%. Profit margin rocketed a 6,341.27% compared to previous quarter when profit margin was -6,816.05%. When comparing revenues to same quarter last year, EyePoint Pharmaceuticals sales marked an exceptional growth and boosted a 161.74%.
|2017-Q1||$0.59 M||-||$-5.14 M-871.2%||-|
|2017-Q2||$0.70 M||18.81%||$-6.12 M-873.0%||19.07%|
|2017-Q3||$0.39 M||-45.08%||$-5.98 M-1554.0%||-2.24%|
|2017-Q4||$0.93 M||142.34%||$-5.78 M-619.7%||-3.36%|
|2018-Q1||$0.93 M||-0.54%||$-6.98 M-751.9%||20.68%|
|2018-Q2||$0.72 M||-22.95%||$-34.43 M-4815.1%||393.38%|
|2018-Q3||$0.49 M||-32.03%||$-33.13 M-6816.0%||-3.78%|
|2018-Q4||$2.44 M||402.47%||$-11.59 M-474.8%||-65.00%|
EyePoint ownershipWhen you are planning to buy shares of a stock, it's worth to have a look its ownership structure.
EyePoint Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.73% of all shares.
In case of EyePoint Pharmaceuticals stock, 58.18% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for EYPT stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to EyePoint:
|Market cap||$147.0 M|
|Total shares||108.1 M|
|Float shares||60.3 M|
|- Institutional holdings (%)||58.2%|
|- Insider holdings (%)||0.7%|
|Shares in short selling||0.0%|
|Tuesday, February 25th, 2020|
|Day range||$1.33 - $1.45|
|Average true range||$0.14|
|50d mov avg||$1.67|
|100d mov avg||$1.77|
|200d mov avg||$1.68|
EyePoint performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For EyePoint, the comparison is made against .